Ποια είναι η τιμή για Biocartis Group N.V. (BCART)

Η τιμή για Biocartis Group N.V. (BCART) είναι $0.343985

Ποια είναι η κεφαλαιοποίηση αγοράς για Biocartis Group N.V. (BCART)

Η κεφαλαιοποίηση αγοράς για Biocartis Group N.V. (BCART) είναι $32.31M

Biocartis Group N.V. (BCART) Έσοδα

Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.

Έτος	Έσοδα	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

Έσοδα

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	Έσοδα	Διαφορά Εσόδων	Χώρα
Thermo Fisher Scientific Inc. TMO.US	$46.34B	-	US
Danaher Corporation DHR.US	$25.11B	-	US
WuXi AppTec Co., Ltd. 603259.SS	-	-	CN
Natera, Inc. NTRA.US	$2.71B	-	US
IDEXX Laboratories, Inc. IDXX.US	$4.55B	-	US

Εταιρεία

Έσοδα

Διαφορά Εσόδων

Χώρα